article thumbnail

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Fierce Pharma

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. Morgan Healthcare Conference. | In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity.

article thumbnail

JPM24, Day 2: BioNTech warns of COVID vaccine sales decline; Alnylam looks to become 'top-tier' biopharma player

Fierce Pharma

Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024. As the J.P. | As the J.P.

Biopharma 297
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Rising Investment in Patient Support Drives a Greater Biopharma Focus on Measurement

Fierce Pharma

A seismic shift has occurred in the healthcare landscape. Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support.

Biopharma 180
article thumbnail

Innovation key for boosting UK biopharma competitiveness

European Pharmaceutical Review

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. Technological solutions and policy recommendations for government have been identified as a way to help make sectors such as biopharma and Medtech more innovative and increase their value added.

article thumbnail

invoX Pharma agrees to acquire biopharma firm F-star Therapeutics for $161m

Pharmaceutical Technology

invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. for each share in cash.

article thumbnail

J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition

MedCity News

Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the investment bank said big pharmas are looking for deals involving de-risked assets.

Biopharma 104
article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

Embarking on the journey from product development to market success in the biopharma industry is no small feat. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launches.